Nurix in the news
custom_AI_solutions_enterprise
Tamtam found 9 recent articles about Nurix.
- Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 6,284 Shares
Nurix Therapeutics' CFO sold shares amid the company reporting a quarterly loss and mixed analyst ratings, while the firm advances cancer and autoimmune therapies.
- Nurix Therapeutics presents data on BTK degrader at ASH meeting
Nurix Therapeutics presented clinical data on its BTK degrader bexobrutideg at the 2025 ASH Hematology Meeting.
- BTIG Reiterates Nurix Therapeutics (NRIX) Buy Recommendation
BTIG maintains a Buy rating on Nurix Therapeutics with a strong price target upside despite declining revenue projections and mixed institutional ownership changes.
- Why Nurix Therapeutics (NRIX) Is Up 5.3% After Advancing Bexobrutideg Trial and Raising $250 Million
Nurix Therapeutics advanced its bexobrutideg trial and raised $250 million, improving its financial runway despite ongoing losses.
- Nurix therapeutics CFO van Houte sells $78,931 in stock
Nurix's CFO sold shares while the company raised $250M to fund clinical trials for a leukemia drug, with analysts raising price targets amid pipeline progress.
- Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $26
Needham analyst Gil Blum keeps a buy rating on Nurix Therapeutics with a $26 target price, backed by a 39.8% success rate and 4.7% average return over the past year.
- BTIG Reiterates Buy Rating for Nurix Therapeutics (NRIX) with $2
BTIG and other analysts maintain a positive outlook on Nurix Therapeutics, targeting $27 per share, reflecting confidence in its cancer and immune disorder therapies.
- 13 Analysts Have This To Say About Nurix Therapeutics
Nurix Therapeutics faces declining analyst price targets and revenue drops amid ongoing development of oral cancer therapies, with mixed financial performance indicators.
- Nurix (NASDAQ: NRIX) to present NX-5948 data in CLL and Waldenström at ASH
Nurix will present updated clinical trial data on NX-5948 for CLL, Waldenström macroglobulinemia, and BTK resistance at the 2025 ASH meeting.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Nurix?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies